CAMBRIDGE, Mass.--(BUSINESS WIRE)--Javelin Pharmaceuticals (AMEX: JAV) today announced dosing of the first patient in a Phase 3 clinical study of PMI-150 (intranasal ketamine) at the Beth Israel Deaconess Medical Center (BIDMC), a teaching hospital of Harvard Medical School. The Principal Investigator is Dr. Zahid Bajwa, Director, Education and clinical pain research, of the BIDMC Comprehensive Cancer Pain Service. The trial is expected to enroll up to 90 patients and is designed to extend published observations by Javelin in a pilot study of PMI-150 in treating breakthrough pain.
